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Abstract: Chromatin accessibility plays a critical factor in regulating gene expression in cancer 
cells. Several factors, including the High Mobility Group A (HMGA) family members, are known 
to participate directly in chromatin relaxation and transcriptional activation. The HMGA1 
oncogene encodes an architectural chromatin transcription factor that alters DNA structure and 
interacts with transcription factors favouring their landing onto transcription regulatory 
sequences. Here, we provide evidence of an additional mechanism exploited by HMGA1 to 
modulate transcription. We demonstrate that, in a triple-negative breast cancer cellular model, 
HMGA1 sustains the action of epigenetic modifiers and in particular it positively influences both 
histone H3S10 phosphorylation by ribosomal protein S6 kinase alpha-3 (RSK2) and histone H2BK5 
acetylation by CREB-binding protein (CBP). HMGA1, RSK2, and CBP control the expression of a 
set of genes involved in tumor progression and epithelial to mesenchymal transition. These results 
suggest that HMGA1 has an effect on the epigenetic status of cancer cells and that it could be 
exploited as a responsiveness predictor for epigenetic therapies in triple-negative breast cancers. 
Keywords: High Mobility Group A; breast cancer; TNBC; epigenetic; RSK2; CBP; histone H3; 
histone H2B 
 
1. Introduction 
Most of the chemical, biological, and mechanical stimuli a cell is subjected to, such as for 
instance hormones, growth factors, cytokines, cell-cell or cell-extracellular matrix contacts, are 
conveyed by signalling pathways to chromatin, leading to the activation of specific transcriptional 
programs. In cancer cells, these signalling networks are perturbed by the misregulation of key 
components, which are responsible for improper responses that constitute oncogenic boosts leading 
to the acquisition of the typical cancer aggressive traits, i.e., the so called cancer hallmarks [1]. A 
rewiring of gene expression is fundamental to acquire these capabilities [1,2]. Chromatin structure 
poses a steric hindrance to the free access of transcriptional factors/co-activators to DNA and it is 
overcome by means of epigenetic mechanisms, which finally lead to chromatin opening [3]. The 
different conformations chromatin can assume are intimately linked to the post-translational 
modifications (PTMs) of the histone tails protruding from the nucleosomes, the primary packaging 
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scaffold of DNA. Indeed, the different combinations of PTMs of histones constitute a code for the 
selective binding of a plethora of different proteins, which finally dictate the accessibility of DNA 
[4]. 
The High Mobility Group A (HMGA) chromatin architectural factors are DNA–binding 
proteins encoded by two different genes: HMGA1 [5], which gives rise to two splicing variants 
(HMGA1a and HMGA1b) [6], and HMGA2 [7], which encodes for the HMGA2 protein (for 
simplicity, we will refer to HMGA1a and HMGA1b jointly as HMGA1). They have been defined as 
oncofetal proteins because of their high expression levels in both embryonic and cancer cells [8,9]. 
These proteins have been intimately associated with the neoplastic transformation process [10,11], 
and their causal role in cancer development has been firmly established both in vitro and in vivo 
[12–15]. 
HMGA proteins participate, by means of protein/DNA and protein/protein interactions, in the 
assembly of nuclear macromolecular complexes, i.e., enhanceosomes, at the level of gene regulatory 
regions [16,17] and modulate, by protein/protein interactions, the activity of important cellular 
regulators [18–20] . Indeed, HMGA1 is able to inhibit the proapoptotic activity of p53 in thyroid 
cancer cells [18] while both HMGA1 and HMGA2 can enhance transcription factor E2F1 (E2F-1) 
activity displacing histone deacetylase 1 (HDAC1) from retinoblastoma-associated protein (pRb) 
and enhancing E2F-1 activity thus overcoming pRb mediated G0 arrest and promoting the 
development of pituitary adenomas [19,20]. HMGA proteins are among the most connected 
proteins in the nuclear environment of transformed cells [21,22], and it is therefore not surprising 
that they are considered key nodes in the chromatin network [23]. 
HMGA1 protein contacts core histones via their protruding tails in the nucleosome context [24]. 
Given the chromatin architectural role of HMGA proteins, the HMGA/histone interaction was 
perceived as very important, especially with respect to the action of HMGA1 in altering the 
positioning/phasing of nucleosomes on specific promoter/enhancer DNA regulatory sequences [24]. 
Surprisingly, this very interesting aspect regarding the HMGA involvement in chromatin structure 
and dynamics was not fully explored. 
Several groups highlighted a prominent role of HMGA1 in breast cancer (BC) development 
and progression (reviewed in [25]), showing its major contribution to cell motility [26–29], stemness 
and self-renewal [29], and epithelial to mesenchymal transition (EMT) [29,30]. Moreover, HMGA1 
was found to promote breast tumorigenesis by affecting the Ras-extracellular signal-related kinase 
(Ras/ERK) mitogenic signalling pathway [31], DNA repair mechanisms [32], alternative splicing of 
estrogen receptor [33], breast cell secretome [34], and nuclear stiffness [35]. In addition, HMGA1 
was found out to act as a signalling molecule in the extracellular environment promoting invasion 
and metastasis [36]. 
In this work, we investigated the relationship between HMGA1 and histones to understand 
whether HMGA1 could promote BC progression through the modulation of epigenetic 
mechanisms.  
2. Results 
2.1. HMGA1 Expression Influences the Histone Code 
Both in vitro and in vivo studies have highlighted the interaction between HMGA1 and 
histones H2A, H2B and H3, pointing out the involvement of amino-terminal histone tails in these 
contacts [24]. HMGA proteins regulate both wide-range and locus-specific chromatin processes, 
both by shaping DNA and by interacting with several other nuclear partners [23,37]. We therefore 
hypothesized that physical contact of HMGA1 with core histones could provide the opportunity to 
affect PTMs of core histone tails, i.e., the histone epigenetic code [4], thus potentially influencing 
epigenetic events. To this purpose, HMGA1 expression was downregulated by small interfering 
RNA (siRNA) in MDA-MB-231 cells, where it is expressed at high levels, and samples were 
analysed for PTMs associated with core histone H3 and H2B tails that have cumulative effects on 
transcriptional regulation. In particular, we investigated marks of transcriptional activation 
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characteristics of the H3 tail, i.e., S10 and S28 phosphorylation (ph) [38–40] and K14 acetylation (ac) 
[41], and others belonging to H2B, such as K5ac and K16ac [42,43]. Conversely, we checked the 
levels of methylated histone H3, particularly H3K9me3 and H3K27me3, which are known 
repressive markers [44–46]. 
As shown in Figure 1A, HMGA1 downregulation clearly impacted the levels of active 
chromatin marks of both H3 (left side) and H2B (right side), whereas repressive marks seemed to be 
largely unchanged. In particular, phosphorylation of H3 and acetylation of H2B were the most 
affected (see Figure 1B for a quantitative evaluation of western blot analyses shown in figure 1A). 
We confirmed the modulation of H3S10ph using a different HMGA1–targeting siRNA, different 
triple-negative breast cancer (TNBC) cellular models (MDA-MB-157 and MDA-MB-468 cells), and a 
different α–H3S10ph antibody (Figure S1). 
The downregulation of both H3S10ph and H2BK5ac was then validated by 
immunofluorescence (IF) analyses performed on MDA-MB-231 cells (Figure S2). Moreover, both 
PTMs appeared to be present in the entire cell population, thus suggesting that, in accordance with 
literature data, they occur mostly in interphasic cells [38–40,42,43]. 
 
Figure 1. High Mobility Group A1 (HMGA1) affects H3 and H2B post-translational modifications in 
MDA-MB-231 cells. (A) Western blot (WB) analyses of MDA-MB-231 cells transfected with control 
(siCTRL—lanes 1) and HMGA1–targeting (siA1_3 or siA1_1—lanes 2 and 3) small interfering RNAs. 
Representative Red Ponceau-stained membranes for loading and quantification control are shown. 
Molecular weight markers (kDa) are indicated. (B) Densitometric analyses of WB signals. Means 
and standard deviations are reported (n = 3). Statistical significances (t-test) are indicated: (*: p < 
0.05; **: p < 0.01). 
2.2. RSK2 Kinase Phosphorylates H3S10 and H3S28 in Interphasic MDA-MB–231 Cells 
We initially focused on elucidating the HMGA1-dependent pathway(s) involved in H3S10 and 
H3S28 phosphorylation. The histone H3 tail is the substrate of many kinases that activate different 
transcriptional programs in response to several stimuli. We concentrated on the mitogen-activated 
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protein kinase (MAPK) pathways since they are responsible for H3 phosphorylation in interphase 
cells [47,48]. Downstream of these pathways, mitogen- and stress-activated kinase 1 (MSK1) and 
ribosomal protein S6 kinase alpha-3 (RSK2) are the proteins principally involved in H3 
phosphorylation [47,49]. The Ras-extracellular signal-related kinase (Ras/ERK) mitogenic signalling 
pathway can activate both MAPK-activated kinases, whereas MSK1/2 can also be activated by p38 
under stress conditions or inflammatory cytokines [49,50]. To determine which MAPK pathway 
was responsible for H3 phosphorylation in our cellular model, we treated MDA-MB-231 cells with 
two inhibitors, U0126 and BIRB796, which block MEK1/2- and p38-dependent phosphorylation 
cascades, respectively [50,51]. As shown in Figure 2A, interphasic H3S10ph and H3S28ph were 
strongly dependent on the activity of MEK1/2 (U0126) and were almost unaffected by p38 
inhibition (BIRB796). Moreover, U0126 treatment blocked the phosphorylation of ERK by MEK1/2 
without affecting HMGA1 levels (Figure 2B). 
 
Figure 2. H3S10ph and H3S28ph are mediated by the extracellular-signal-regulated 
kinase/ribosomal protein S6 kinase alpha-3 (ERK/RSK2) pathway in MDA-MB-231 cells. Western 
blot (WB) analyses performed with MDA-MB–231 lysates. (A) Cells treated for 24 h with 10 µM 
U0126 (lane 2), 10 µM BIRB796 (lane 3), or dimethyl sulfoxide (DMSO) as control (CTRL, lane 1). (B) 
Cells treated for 24 h with 10 µM UO126 (lane 2) and DMSO as control (CTRL, lanes 1). (C) Cells 
transfected with control (siCTRL, lane 1) or HMGA1–targeting (siA1_3, lane 2) small interfering 
RNAs. The HMGA1 silencing efficacy of siA1_3 treatment is shown in Figure 1. (D) Left side: cells 
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treated for 24 h with 10 µM SB747651A (lane 2) and DMSO as control (CTRL, lanes 1). Right side: 
cells treated for 24 h with 10 µM BI–D1870 (lane 2) and DMSO as control (CTRL, lanes 1). 
Representative red ponceau-stained membranes are shown as loading and quantification controls. 
Molecular weight markers (kDa) are indicated on the left. All WB experiments were performed in 
biological triplicate, providing consistent results. Representative images are shown. (E) Summary of 
all the inhibitors used and their targets within the studied pathways. 
Since we demonstrated that interphasic H3S10ph and H3S28ph were mediated by the 
Ras/Raf/MEK/ERK pathway in MDA-MB-231 cells (Figure 2A), we tested whether ERK activation 
was dependent on HMGA1 expression. Therefore, we silenced the expression of HMGA1 and 
analysed ERK1/2 activation. Results clearly indicate that HMGA1 silencing (Figure 2C) did not alter 
ERK expression or ERK phosphorylation, suggesting that HMGA1 acts downstream of ERK 
activation. Moreover, to exclude that HMGA1 could affect the expression of the two main 
downstream kinases responsible for H3 phosphorylation upon ERK pathway activation, i.e., 
MSK1/2 [47] and RSK2 [49], the same extracts from MDA-MB-231 cells silenced for HMGA1 
expression, were analysed for MSK1 and RSK2 expression. The results show that HMGA1 silencing 
substantially affected neither MSK1 nor RSK2 protein expression (Figure 2C). 
To determine the contribution of MAPK-activated protein kinases to the interphasic 
phosphorylation of H3S10 and H3S28, we treated MDA-MB-231 cells with specific inhibitors of 
MSK1/2 (SB747651A, [52]) and RSK isoforms (BI-D1870, [53]). In contrast to MSK1/2, RSK isoforms 
inhibition drastically impaired both H3 phosphorylations (Figure 2D). The H3S10ph decrease was 
observed within few hours of inhibitor treatment, suggesting that these kinases have a direct role in 
histone phosphorylation rather than being the result of an indirect effect due to reduced 
proliferation (Figure S3A). RSK2 is one of the main kinases able to phosphorylate histone H3S10 
[49] and its specific involvement in this context was confirmed by comparing the silencing of 
MSK1/2 and RSK2 (Figure S3B). A summary of all the inhibitors used and their targets within the 
studied pathways is shown in Figure 2E. 
2.3. RSK2 Impairment Mimics the Effects of HMGA1 Silencing 
To confirm that interphasic H3 phosphorylation is necessary for gene expression activation, we 
investigated whether the silencing, or inhibition, of RSK2 affects a subset of genes (Aurora kinase B, 
AURKB; Kinesin-like protein KIF23, KIF23; Chromosome-associated kinesin KIF4A, KIF4A; 
Centromere protein F, CENPF) belonging to the HMGA1 signature that we previously identified in 
BC cells [29] and from now on referred to as the HMGA1 subset signature (Hsss). Therefore, 
MDA-MB-231 cells were collected after RSK2 silencing or upon treatment with BI-D1870, and the 
expression of these genes was analysed (Figure 3).  
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Figure 3. High Mobility Group A1 (HMGA1) and ribosomal protein S6 kinase alpha-3 (RSK2) 
regulate a common set of genes. Gene expression analyses performed by qRT-PCR on MDA-MB-231 
cells transfected with (A) control (siCTRL) or HMGA1–targeting (siA1_3) small interfering RNAs, 
(B) control (siCTRL) or RSK2–targeting (siRSK2) siRNA, or (C) treated for 24 h with BI–D1870 10 
μM or dimethyl sulfoxide (CTRL) as a control. siRNA-treated cells were harvested after 72 h. 
Expression of the HMGA1 subset signature (Hsss - AURKB, KIF23, KIF4A, CENPF), RSK2, and 
HMGA1 genes was analysed using glyceraldehydes-3-phosphate dehydrogenase (GAPDH) or 
cyclophilin-33 (CYP33) as internal reference genes. Data are represented as relative gene expression 
values with respect to control samples. Standard deviations (n = 3) and statistical significance (t-test) 
are indicated (p-values: * : p < 0.05; ** : p < 0.01; *** : p < 0.001). 
The expression of Hsss was significantly downregulated upon RSK2 silencing (Figure 3B) and 
BI-D1870 treatment (Figure 3C). As a control, the expression of Hsss was analysed upon HMGA1 
silencing (Figure 3A) together with another set of genes whose expression was not altered by 
HMGA1 (Figure S4A). To confirm that the specificity of gene expression activation is due to 
RSK2-dependent phosphorylation of H3, the Hsss was analysed upon MSK1/2 silencing and no 
effect on its level of expression was observed (Figure S4B and C). The dependence of Hsss by 
HMGA1 and RSK2 was confirmed in MDA-MB-157 cells (Figure S5A). 
We reported a drastic phenotypic change, the so-called mesenchymal to epithelial transition 
(MET), as a consequence of the downregulation of HMGA1 expression in mesenchymal-like TNBC 
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MDA-MB–231 cells. This change was associated with reduced cell motility and invasiveness [29]. 
We therefore hypothesized that RSK2-dependent histone H3 phosphorylation could mediate the 
activation of a transcriptional program involved in MET. Indeed, MDA-MB-231 cells treated with 
BI–D1870 underwent substantial changes in their aspect (Figure 4A): from a spindle-shaped 
morphology to a regular and flattened one, reflecting a typical MET very close to the one obtained 
by HMGA1 downregulation [29]. In addition, the change in cell morphology occurred very early 
after BI–D1870 treatment (4 h, Figure S5B). BI-D1870 treatment slowed down cell proliferation, as 
evidenced by a 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]-based 
(MTS) assay (Figure 4B) and, in addition, it significantly impaired cell migration as evidenced both 
by wound–healing (Figures 4C and D) and transwell assay (Figures 4E and F).  
Moreover, qRT-PCR analyses showed the down regulation of a set of mesenchymal markers 
(vimentin, VIM; zinc finger protein SNAI2, SNAI2, and lymphoid enhancer-binding factor 1, LEF1) 
(Figure 4G), thus supporting a MET. Treatment of another TNBC cell line, i.e., MDA-MB-157, with 
BI-D1870 reproduced the same effects observed in MDA-MB-231; in particular, albeit at a lower 
extent, we observed the same morphological transition, a decrease in cell proliferation, and the 
impairment of cell motility (Figure S5C–F). Overall, these data support that RSK2-dependent 
interphasic phosphorylation of H3 plays a crucial role in the activation of an HMGA1-driven 
transcriptional program that is associated with cell aggressiveness. 
HMGA1 is known to be involved in the modulation of the expression of several genes by 
directly binding to cis regulatory regions. We chose three different genes that are part of the 
HMGA1 signature [29] and that we demonstrated to be transcriptionally regulated by HMGA1: 
G1/S-specific cyclin E2 (CCNE2) [54], plasminogen activator inhibitor 1 (SERPINE1) [34], and 
aurora kinase B (AURKB) [29]. By using the RSKs inhibitor BI–D1870, whose effects closely 
resemble the gene transcriptional and biological effects achieved with HMGA1 silencing, we 
demonstrated that H3S10ph is specifically decreased in several regulatory regions of these genes 
(Figure 5), thus suggesting a chromatin–related involvement of this epigenetic mark in gene 
expression regulation. 
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Figure 4. Ribosomal protein S6 kinase alpha-3 (RSK2) activity is essential in MDA-MB–231 cells to 
maintain a mesenchymal phenotype and cell motility. (A) Optical microscope images of 
MDA-MB-231 cells treated for 24 h with BI-D1870 10 µM. Dimethyl sulfoxide (DMSO)–treated cells 
are shown as a control. (B) 
[3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium]-based 
(MTS) assay of MDA-MB-231 cells treated with BI-D1870 10 µM in comparison with DMSO 
treatment as a control (n = 6). (C) Wound–healing assay of MDA-MB-231 cells treated with BI-D1870 
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10 µM. DMSO–treated cells are shown as a control. Representative images of start (0 h) and end (8 
h) time points are reported. (D) Quantitative evaluation of the wound–healing assay. Data are 
represented as the means of the percentage of wound closure relative to the start time point. The 
experiment was performed in technical duplicate and biological triplicate. (E) Transwell assay of 
MDA-MB-231 cells treated with BI-D1870 10 µM. DMSO–treated cells are shown as a control. Two 
representative images are reported for each treatment. (F) Quantitative evaluation of the Transwell 
assay (n = 4, technical sextuplicate). (G) Gene expression analyses performed by qRT-PCR on 
MDA-MB-231 cells treated for 24 h with BI–D1870 10 μM or DMSO as a control. Expression of the 
epithelial to mesenchymal transition (EMT) markers vimentin (VIM), zinc finger protein SNAI2 
(SNAI2), and lymphoid enhancer-binding factor 1 (LEF1) genes was analysed using 
glyceraldehydes-3-phosphate dehydrogenase (GAPDH) as internal reference genes. Data are 
represented as relative gene expression values with respect to control samples (n = 3). Standard 
deviations and statistical significance (t-test) are indicated (p-values: ** : p < 0.01; *** : p < 0.001). 
 
Figure 5. Ribosomal protein S6 kinase alpha-3 (RSK2) is responsible for H3S10 phosphorylation at 
the level of genes that are transcriptionally modulated by High Mobility Group A1 (HMGA1). 
Chromatin immunoprecipitation (ChIP)-qPCR experiments performed on MDA-MB-231 cells 
treated with the RSK2 inhibitor BI-D1870. Cell lysates from control and BI–D1870–treated cells were 
immunoprecipitated both with α–histone H3S10ph antibody and non-specific immunoglobulins 
(IgG) as a control (CTRL). Immunoprecipitated DNA was amplified with primers targeting the 
indicated genomic region within three HMGA1 target genes (G1/S-specific cyclin E2, CCNE2; 
plasminogen activator inhibitor 1, SERPINE1; aurora kinase B, AURKB). Enrichments for the 
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individual antibodies used are plotted as percentage of input DNA. Means, standard deviations (n = 
3), and statistical significance (t-test) are indicated (* : p < 0.05; ** : p < 0.01; *** : p < 0.001). 
2.4. CBP Impairment Mimics the Effects of HMGA1 Silencing 
After establishing the pathway involved in HMGA1–dependent phosphorylation of H3, we 
moved to H2B. Histone H2B acetylation has been extensively linked to the activity of two distinct 
histone acetyltransferases (HATs), CREB-binding protein (CBP) and its paralogue p300 (E1A 
binding protein p300), which display strong sequence similarities and functional homologies and 
could either play overlapping or unique functions [55,56]. We investigated whether the acetylation 
status of H2B in MDA-MB-231 cells was dependent on CBP/p300 activity (Figure 6).  
For this purpose, we used the pyrazolone-containing small molecule inhibitor C646 [57]. 
Considering that C646 competes with acetyl-CoA for CBP/p300 binding [58], cells were 
serum-starved for 24 h prior to C646 treatment to lower acetyl coenzyme A (acetyl-CoA) levels and 
increase the efficiency of C646 inhibition. Cells were treated with C646 or DMSO as a vehicle 
control and analysed for H2BK5ac. Figure 6A shows a notable decrease in the levels of H2BK5 
acetylation, while total H2B protein levels remained almost unchanged (Figure 6A, left panel).  
Inhibition of CBP/p300 concomitantly led to the downregulation of Hsss in MDA-MB-231 cells 
(Figure 6A, right panel), thus suggesting that the CBP/p300-mediated acetylation of H2B could be 
involved in the activation of HMGA1-linked transcriptional programs. 
Despite their high degree of homology, CBP and p300 also have non-redundant in vivo 
functions. To dissect the roles played by these two acetyltransferases within the 
HMGA1–dependent epigenetic reprogramming in BC cells, we silenced the expression of CBP and 
p300 independently and examined both H2B acetylation levels and the expression of Hsss. When 
the expression of CBP (Figure 6B, left panel) and p300 (Figure 6C, left panel) was silenced in 
MDA-MB-231 cells, there were a significant downregulation of H2BK5ac levels compared to control 
cells. Interestingly, Hsss was found to be significantly downregulated only upon CBP silencing 
(Figure 6B, right panel), whereas its expression was not altered in p300-silenced cells (Figure 6C, 
right panel). These data suggest that H2B acetylation relies both on the activity of CBP and p300 in 
MDA-MB-231 cells, but only CBP is involved in the gene expression regulation of Hsss. The 
dependence of Hsss by CBP was confirmed in MDA-MB-157 cells (Figure S5A). 
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Figure 6. CREB-binding protein (CBP) is linked to the gene expression regulatory role of High 
Mobility Group A1. (A, B, and C—left side) Western blot (WB) analyses performed with 
MDA-MB–231 cell lysates. Cells were grown with complete medium (lane 1) or serum-starved 
medium (lanes 2, 3 and 4) for 24 h before treatment with 20 μM C646 or 0.2% dimethyl sulfoxide 
(DMSO) as a control (CTRL). UT (untreated) represents cells treated neither with C646 nor with 
DMSO (A—left side). MDA-MB–231 cell lysates silenced for CBP and p300 (siCBP and sip300) and 
their relative controls (siCTRL) (B and C—left side, respectively). All WB experiments were 
performed in biological triplicate, providing consistent results. Representative images are shown. 
(A, B, and C, right side) qRT-PCR analyses of serum-starved MDA-MB-231 cells treated for 24 h 
with 20 μM C646 (A, right side) MDA-MB-231 cells silenced for CBP (B, right side) or p300 (C, right 
side) and their respective controls (DMSO and siCTRL). The four HMGA–signature genes (Hsss) 
were analysed together with CBP and p300. Glyceraldehydes-3-phosphate dehydrogenase 
(GAPDH) or cyclophilin-33 (CYP33) were used as internal reference genes. Mean, standard 
deviations (n = 3), and statistical significance (t-test) are indicated (* : p < 0.05; ** : p < 0.01; *** : p < 
0.001). 
2.5. Histone H3S10ph and Histone H2BK5ac are Interdependent PTMs 
Histone acetylation and phosphorylation have been coupled to transcriptional activation. CBP 
has been shown to interact with unphosphorylated RSK2, forming a complex where both CBP and 
RSK2 are kept inactivated. Upon mitogenic stimuli leading to the phosphorylation of RSK2 at S227, 
RSK2 and CBP dissociate and drive gene expression activation by acting as a histone kinase and 
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histone acetyltransferase (HAT), respectively [59]. Our data provide evidence that HMGA1 
regulates gene expression in MDA-MB–231 cells through the modulation of both RSK2 and CBP 
activities. Therefore, we asked whether the two modifications were somehow interconnected. Since 
RSK2 activity relies on the activation of the ERK1/2 pathway, we evaluated whether this pathway 
was also involved in controlling H2B acetylation. Inhibition of the ERK1/2 pathway by the inhibitor 
U0126 also affected H2BK5ac in both MDA-MB–231 and MDA-MB–157 (Figure 7A). Moreover, 
RSKs inhibition by BI-1870 reduced H2BK5ac levels, and CBP/p300 inhibition by C646 
downregulated H3S10ph levels (Figure 7B). Overall, these results suggest that in MDA-MB-231 
cells, the presence of HMGA1 is relevant for both RSK2 and CBP activities and that together, these 
two factors cooperate in the expression of genes critical for tumor cell migration and 
aggressiveness. In order to clarify the interdependence of RSK2 and CBP we silenced in 
MDA-MB-231 cells both CBP and RSK2 evaluating the effects towards the gene expression of 
HMGA1, CBP, and RSK2 (Figure 7C). The silencing of both CBP and RSK2 did not affect HMGA1 
gene expression level, and the silencing of RSK2 did not affect CBP gene expression. On the 
contrary, the CBP silencing caused a decrease in RSK2 gene expression level. In MDA-MB-157 cells 
the RSK/CBP interdependence is almost identical to that observed in MDA-MB-231. However, 
differently from what occurs in MDA-MB-231, the HMGA1 gene expression seems to be under the 
control of both RSK2 and CBP (Figure 7C). 
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Figure 7. Ribosomal protein S6 kinase alpha-3 (RSK2) and CREB-binding protein (CBP) are 
interconnected epigenetic writers in MDA-MB–231 cells. Western blot (WB) analyses performed 
with MDA-MB–231 and MDA-MB–157 lysates. (A) Cells treated for 24 h with 10 μM U0126 (lane 2) 
or dimethyl sulfoxide (DMSO) as a control (CTRL, lane 1). (B) MDA-MB–231 cells were treated with 
BI–D1870 and C646 (lane 2), and respective controls (CTRL, lane 1) and WB analyses were 
performed on cellular lysates. Representative red ponceau-stained membranes are shown as loading 
and quantification controls. Molecular weight markers (kDa) are indicated. All WB experiments 
were performed in triplicate, providing consistent results. Representative images are shown. (C) 
qRT-PCR analyses of MDA-MB-231 and MDA-MB-157 cells silenced for CBP (siCBP), RSK2 
(siRSK2), or treated with a control small interfering RNA (siCTRL). The expression of HMGA1, 
RSK2, and CBP were analysed. Glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was used 
as internal reference gene. Mean, standard deviations (n = 3), and statistical significance (t-test) are 
indicated (** : p < 0.01; *** : p < 0.001). 
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2.6. HMGA1 Modulation of RSK2 and CBP Activities Is Likely to Occur by a Direct Mechanism and Not by 
Affecting Their Gene or Protein Expression Levels 
We reasoned that HMGA1 could influence histone PTMs by different mechanisms: HMGA1 
could control RSK2/CBP gene expression or modulate chromatin accessibility and recruitment onto 
DNA. To check whether HMGA1 could have a role in modulating the gene expression levels of 
these two enzymes, we silenced the expression of HMGA1 in MDA-MB–231 cells and looked at 
RSK2 and CBP mRNA levels. As shown in Figure 8A, upon HMGA1 downregulation, there was a 
slight downregulation of RSK2 mRNA expression, whereas CBP and p300 mRNAs were not 
downregulated but rather appeared slightly upregulated. 
The downregulation of RSK2 mRNA opened up the possibility that the decrease in histone H3 
S10 phosphorylation could be due to a decrease in the protein expression level of RSK2. The 
mechanism of RSK2 activation is complex; it relies on ERK activity, but the last kinase responsible 
for RSK2 activation is 3-phosphoinositide-dependent protein kinase-1 (PDK1), which 
phosphorylates RSK2 S227 in the N–terminal kinase domain [60]. Figure 8B shows that both the 
protein expression level of RSK2 and its phosphorylation at S227 did not significantly change after 
HMGA1 silencing. As additional proof that HMGA1 does not affect RSK2 activation, we checked 
the nuclear/cytoplasmic localization of RSK2. HMGA1 silencing did not affect the intracellular 
localization of RSK2, which, contrary to what we expected, turned out to be slightly, but not 
significantly, more nuclear (Figure 8C).  
 
Figure 8. High Mobility Group A1 (HMGA1) modulates histone post-translational modifications 
(PTMs) acting downstream of Ribosomal protein S6 kinase alpha-3 (RSK2) phosphorylation. (A) Relative 
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gene expression data regarding HMGA1, RSK2, CBP, and p300 obtained by reverse 
transcription-quantitative polymerase chain reaction (RT-qPCR) analyses of MDA-MB-231 samples 
treated with siCTRL or siA1_3. Mean and standard deviation (n = 3) are reported relative to the 
control sample. Glyceraldehydes-3-phosphate dehydrogenase (GAPDH) was used as an internal 
reference gene. Significance was assigned by Student’s t-test (*: p < 0.05; **: p < 0.01; ***: p < 0.001). 
(B) Western blot (WB) analysis of MDA-MB-231 lysates upon HMGA1 silencing (lane 2, siA1_3) or 
control (lane 1, siCTRL). Panels are representative of a biological triplicate, and the red 
ponceau-stained membrane is shown as a loading and quantification control. HMGA1 levels have 
been previously verified (see Figure 1). The histogram graph displays WB band densitometry values 
normalized to red ponceau-stained lysate lanes and relative to control samples. Mean and standard 
deviations (n = 3) are reported. Significance was assigned by Student’s t-test. (C) 
Immunofluorescence analysis performed with MDA-MB-231 cells treated with control siRNA 
(siCTRL) and with siRNA targeting HMGA1 (siA1_3). Representative fields are shown. Staining: 
RSK2 (green), DNA (Hoechst, blue). The nuclear/cytoplasm mask is reported. Results are shown as 
percentages of integrated densities (IntDens) of each area (nucleus or cytoplasm) with respect to the 
whole cell integrated density and reported as a mean of three different regions of interest for each 
sample type (siCTRL or siA1_3). The efficiency of HMGA1 silencing has been ascertained by WB 
and is shown on the right side. (D) HMGA1 and RSK2 co-immunoprecipitation (co–IP) analysis 
performed with MDA-MB-231 lysates. Input lysate was loaded in lane 1. Lanes 2 and 3 display 
immunoglobulins (IgG) immunoprecipitates (controls), while lanes 4 and 5 display HMGA1 
immunoprecipitates. Lanes 3 and 5 show co–IPs performed with lysates treated with DNase I. WB 
analyses of HMGA1 and RSK2 are reported. The efficiency of DNase I digestion is shown on the 
right side. 
These data strongly suggest that HMGA1 could affect both H3S10ph (and H3S28ph) and 
H2BK5ac by a mechanism involving the recruitment of RSK2/CBP onto DNA. It was previously 
demonstrated that HMGA1 is a key modulator of CBP recruitment onto chromatin [17]; therefore, 
we focused on the HMGA1/RSK2 interaction. To this end, we performed co-immunoprecipitation 
analyses (co–IPs) in the presence or absence of DNase I to discriminate between a direct and a 
chromatin–mediated interaction. As reported in Figure 8D, despite the presence of an unspecific 
band at a higher molecular weight with respect to RSK2 in the control experiment (lane 2), RSK2 
was efficiently immunoprecipitated in the presence of DNA (lane 4), whereas it was not when DNA 
was digested (lane 5). Therefore DNA mediates the HMGA1/RSK2 interaction, but the two proteins 
lay very close to each other since the average length of the fragmented DNA (600 bp) encompasses 
approximately three nucleosomes (right part of panel 8D). 
3. Discussion 
The analysis of histone marks distribution among different BC molecular subtypes provides a 
specific chromatin signature defined by the pattern of activating or repressing PTMs. The 
chromatin distribution of these PTMs is indicative of the activation of distinct biological pathways 
and could also provide insights into clinical parameters (relapse-free survival and outcome) when 
applied to BC patients [61]. 
Since HMGA proteins bind nucleosome core particles [24] and HMGA1 expression inversely 
correlates with the overall survival in BC [62], our study aimed to evaluate possible epigenetic 
mechanisms by which this oncoprotein could contribute to the progression of TNBC, a particularly 
aggressive and heterogeneous intrinsic molecular subtype of BC with poor prognosis. 
It has been previously demonstrated that: (i) HMGA proteins preferentially contact histones 
H3, H2A, and H2B, (ii) up to four HMGA1 molecules can bind to a single nucleosome, (iii) the 
binding occurs in a non-cooperative manner, probably on the “front face” of the nucleosome at the 
entry/exit site of the wrapped DNA, (iv) the acidic C-terminal tail of HMGA1 is not involved in this 
interaction, and (v) DNA/HMGA1 interactions are involved [24]. It was subsequently demonstrated 
that HMGA1 protein can bind to nucleosomal DNA and that it alters the nucleosome structure by 
changing the periodicity of nucleosomal DNA [63]. Moreover, HMGA proteins have already been 
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linked to epigenetic alterations. In detail, HMGA2 has been linked to histone acetyl transferase 
(HAT) expression regulation in pancreatic ductal adenocarcinoma, which is in turn linked to 
increased levels of H3K9ac and H3K27ac in the fibrotic region. Downregulation of HMGA2 
expression caused a reduction of acetylated H3 and sensitized cells to gemcitabine [64]. In addition, 
HMGA2 was shown to participate in the repression of the cadherin-1 (Cdh1) gene both by binding 
to the Cdh1 promoter and favouring the recruitment of the DNA (cytosine-5)-methyltransferase 3A 
(DNMT3A) and by binding to transcriptional repressor CTCF (CTCF) and displacing it from DNA, 
thus contributing to the EMT also via an epigenetic mechanism [65]. More recently, in a proteomic 
screening aimed at evaluating the interaction landscape of histones, it was demonstrated that 
HMGA1 was crosslinked with more than one core histone [66], thus suggesting intimate contact of 
HMGA1 with nucleosomes. 
Our main findings in this work are the following:  
a) HMGA1 silencing causes the downregulation of a series of histone post-translational 
modifications, i.e., mainly histone H3 S10 and S28 phosphorylation and histone H2B 
K5, K16, and K20 acetylation; 
b) In the MDA-MB-231 cellular model these modification are due to the activity of RSK2 
and CBP/p300; 
c) The silencing of RSK2 and CBP phenocopies the effect of HMGA1 silencing towards a 
set of HMGA1 regulated genes while p300 silencing does not; 
d) Impairment of RSK2 activity by means of the RSKs inhibitor BI-D1870 is responsible 
for a  decrease of histone H3 S10 phosphorylation at specific regulatory regions of 
HMGA1 regulated genes;  
e) HMGA1 does not modulate the gene/protein expression level of RSK2 and CBP and 
HMGA1 does not modulate the nuclear localization of RSK2 neither its activation 
status (i.e., RSK2 S227 phosphorylation level); 
f) Impairment of RSK2 activity by means of the RSKs inhibitor BI-D1870 is responsible 
for MET; 
g) HMGA1 and RSK2 interact in a DNA-dependent way. 
Altogether these data suggest a role of HMGA1 in modulating the activity of RSK2 and CBP at 
chromatin level. H3S10ph is a convergence point of several signalling cascades (reviewed in [67]). 
H3S10ph and H3S28ph affect the adjacent docking sites, H3K9me3 and H3K27me3, for HP1 and 
Polycomb group proteins [38,40] and are usually referred to as epigenetic molecular switches. It has 
also been demonstrated that H3S10ph cooperates synergistically with histone acetylation in 
providing a transcriptionally competent environment [39]. 
RSK2 has emerged as a specific therapeutic target for metastatic TNBCs, and the use of an 
RSK2 inhibitor has shown to reduce cell proliferation, survival in a non-adherent environment, and 
migration [68]. Inhibition of RSK2 suppresses tumor-initiating cell growth and promotes cell death 
[69]. Some authors showed that 85% of TNBC patients exhibit activation of RSK2 (S227ph) in a 
panel of high-grade BC samples. Moreover, RSK2 inhibitor treatment could overcome the side 
effects of MEK/ERK inhibitors in clinical trials: in fact, the efficiency of MEK/ERK inhibition is often 
lowered by feedback loop activation of the phosphoinositide-3-kinase–protein kinase B/AKT 
(PI3K-PKB/AKT) pathway [70]. 
CBP/p300 are versatile HATs with context-dependent functions, and indeed, the large 
multiprotein complexes they belong to usually dictate their functional outcome. In fact, CBP/p300 
mediates the tumor suppressor function of p53 [71], Forkhead box protein O3 (FOXO3A) [72] and 
Breast cancer type 1 susceptibility protein (BRCA1) [73], while on the other hand, together with 
c-Myc [74], c-Myb [75] and androgen receptor (AR) co-activators [76], they can promote cancer 
progression. HAT inhibition has been pursued as a therapeutic tool in the fight against cancer: 
bisubstrate inhibitors (mimicking the two HAT substrates, the acetyl-CoA and the lysine-containing 
peptide connected by a linker), natural compounds (anacardic acid, curcumin, garcinol), small 
molecule inhibitors (C646), and protein/protein interaction inhibitors are currently being 
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investigated in different tumor types, despite such limitations as instability, low cell permeability, 
selectivity, and low potency [77]. In vivo, the CBP/p300 inhibitor L002 suppresses tumor growth 
and recurrence in MDA-MB-468 mouse xenograft models [78]. Although both CBP and p300 can 
modulate H2BKac, we found CBP to be responsible for HMGA1 signature regulation, and these 
results underline the different specificities gained by different HATs. 
Our results confirm the cooperation between RSK2 and CBP in histone modification regulation 
in the TNBC cellular model. In detail, levels of H3S10ph and H2BK5ac are reciprocally modulated 
by HAT and kinase activities and both decreased upon HMGA1 silencing while the gene/protein 
expression level of RSK2 and CBP seems not be affected. Moreover, inhibition of CBP or RSK2 
mirrors the effects obtained by HMGA1 silencing, i.e., the regulation of a common set of genes and 
gross morphological cellular changes. Interestingly, we found that the silencing of RSK2 does not 
modulate CBP expression, but RSK2 activity impairment leads to the down regulation of histone 
H2B K5 acetylation. In our opinion these experimental evidences suggest that the RSK2/CBP 
interplay happens directly onto chromatin and is not due to an effect at transcriptional level, effect 
that cannot be excluded when CBP is silenced since we demonstrated that upon CBP silencing 
RSK2 gene expression is lowered. 
These data should prompt us to rethink the role of HMGA proteins as chromatin architectural 
factors: they should be regarded not only as DNA–binding factors that directly bind to DNA and 
modify its structure, thus favouring the landing of other transcription factors, but also as 
multifaceted chromatin organizers (Figure 9). We demonstrated that the silencing of HMGA1 
causes a reduction of histone H3S10ph and histone H2BK5ac and proved that these two 
modifications are dependent on the activity of RSK2 and CBP/p300. It was previously demonstrated 
that both ERK1/2 and RSK2 were promoter-bound kinases and suggested that the positioning of 
kinases in such locations could allow them to target substrates not otherwise accessible [79]. 
CBP/p300 is a well known transcriptional coactivator, it is recruited onto chromatin throughout 
interaction with transcription factors and is generally involved in the organization of a bridge 
between the promoter/enhancer bound factors and the general transcription factors (reviewed in [80]). 
Several mechanisms could explain this HMGA1-mediated epigenetic effect. The simplest one is that 
given the ability of HMGA1 to bind to nucleosomes it could organizes the assembly of a 
nucleosome-bound complex that in turn could recruit RSK2 and CBP onto chromatin. However, 
HMGA1 has been also demonstrated to be able to enhance the binding of transcription factors 
throughout its ability to confer conformational changes to transcription factor consensus sequences 
or via direct protein-protein contacts, for example facilitating nuclear factor-kappa-B (NF-κB) DNA 
binding [81] or binding to serum response factor (SRF) and changing its DNA binding properties [82]. 
Moreover, it was also demonstrated that HMGA1 is involved in perturbing DNA topology and 
influencing long-range enhancer transcriptional activity by organizing DNA loops [83]. Our data 
demonstrated that the final output of HMGA1 action is a change in the post-translational 
modifications of histones and this implies that the effect of HMGA1 is towards chromatin but the 
exact mechanism behind this event is not still clarified and we do not exclude the possibility that 
multiple HMGA1-mediated mechanisms act at the same time. 
The possibility of a chromatin-mediated mode of action of HMGA1 opens the need to rethink 
the possible effect of HMGA1 PTMs towards chromatin binding. HMGA proteins are modulated by 
a large amount of PTMs (reviewed in[84]), some of which affect the entire bulk of HMGA proteins 
[85,86]. Most of the work carried out to decipher the role of HMGA PTMs has been performed by 
evaluating their effect on direct DNA binding [84]. Intriguingly, in vivo data regarding the effect of 
HMGA1 phosphorylation have demonstrated exactly the opposite of what has been demonstrated 
in vitro: HMGA1 phosphorylation increases the chromatin residence time of HMGA1 [87], data in 
sharp contrast to the well–documented decrease in DNA–binding affinity upon HMGA 
phosphorylation [84]. 
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Figure 9. Expanding High Mobility Group A1 (HMGA1) chromatin functions. HMGA1 participates 
in the chromatin opening process by displacing histone H1 from chromatin via a competitive 
mechanism. Once bound to nucleosomes and/or DNA, HMGA1 is involved in the recruitment of 
transcription factors (TFs) and in the formation of protein platforms for the landing of other 
chromatin proteins [17,23]. In this work, we provided evidence that in triple negative breast cancer 
(TNBC) cells HMGA1 could be an essential co-factor for conveying onto chromatin ribosomal 
protein S6 kinase alpha-3 (RSK2) and CREB-binding protein (CBP) activities. 
HMGA1 is usually expressed at very high level in cancer cells (up to a ratio of 1/5 with histone 
H1 [88]. It displaces histone H1, binds to DNA and chromatin (nucleosomes) and in this way it 
facilitates the assembly of chromatin/DNA-bound macromolecular complexes, which are mainly, 
but not only, involved in transcriptional activation. This chromatin architectural activity could 
allow HMGA1 to participate in the delivery toward chromatin of signals from other oncogenic 
pathways. Limiting our discussion to histone H3 S10 phosphorylation, it is worthwhile to mention 
that RSK2 is not the only kinase able to deposit this PTM. MSK1 is known to be a downstream 
effector of the RAS pathway and to be recruited onto chromatin as part of macromolecular 
complexes that, for instance include CBP/p300, NF-κB, and transcription factor AP-1 (AP1), or ERK 
and progesterone receptor (PR) [89,90]. Moreover, MSK1 was shown to be activated also in a 
protein kinase C (PKC) dependent way [91]. Inhibitor of nuclear factor kappa-B kinase subunit 
alpha (IKK-alpha) is recruited onto chromatin by means of a NF-κB mediated mechanism and 
therein is involved in the phosphorylation of histone H3 S10 [92,93]. IKK-alpha is known to be 
activated by a plethora of different stimuli (reviewed in [94]). Aurora kinase B, is mainly involved 
in mitosis, but it has a role also in interphasic cells where, for instance it is recruited to several 
promoters by a thyroid hormone (T3)-dependent mechanism [95]. Moreover, as concerns AURKB, 
it is worthwhile to notice that HMGA1 is involved in the gene transcriptional regulation of AURKB. 
In addition, RSK2 has a prominent role in the activation of the transcription factor Y-box binding 
protein-1 (YB-1) which is a main factor leading to the development of basal-like cancer [69,96,97]. 
Albeit in a different cellular model, i.e., in non-small-cell lung cancer (NSCLC) cells A549, it is 
intriguing that both HMGA1 and YB-1 have been demonstrated to bind to the promoter of cyclin 
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D1 and to be responsible for its transcriptional regulation [98,99]. In breast cancer cells it was 
demonstrated that chromatin remodelling is upstream of YB-1 landing onto promoters [97]. Albeit 
at a speculative level, HMGA1 could be one of the chromatin factors cooperating with YB-1 in 
breast cancer onset and development. We demonstrated that HMGA1 is involved in maintaining a 
mesenchymal phenotype and to confer aggressive and stemness traits to TNBC cells [29] and that 
part of this activity is performed by modulating a downstream mediator of the Hippo pathway, i.e., 
YAP [54]. In addition, we showed that a set of HMGA1-dependent genes constitute a molecular 
signature with prognostic value in breast cancers [28] and HMGA1 expressing cells secreted 
glycosylated factors involved in modulating cell motility and invasiveness [34]. Very recently we 
demonstrated that HMGA1 is involved in modulating breast cancer cells nuclear stiffness trough a 
mechanism involving histone H1 [35] and that it drives also angiogenic properties acting in 
cooperation with forkhead box protein M1 (FOXM1) [100]. Overall, HMGA1 exerts pleiotropic 
oncogenic effects in MDA-MB-231 cells, which have been extended to other TNBC cells. In this 
work we continued this characterization of the oncogenic role of HMGA1 exploring an additional 
mechanism, i.e., the contribution of HMGA1 to the epigenetic status of cancer cells. We focused on 
MDA-MB-231 cells because they are triple-negative and basal-like breast cancer cells and we 
previously showed, by performing a bioinformatic analysis of a primary breast cancer public 
microarray data collection (1881 different samples), that HMGA1 mRNA levels were higher in the 
basal-like than the HER2+, the luminal A and B, and normal-like subtypes [29]. For sure one of the 
limitation of this study is that it mainly relies upon a single cellular model, however, we speculate 
that it would not be surprising to find out that HMGA1 concurs with the same mechanism in 
conveying to chromatin signals originating from other oncogenic pathways that exploit different 
actors. 
4. Materials and Methods  
4.1. Cell Cultures and Treatments 
The breast cancer cell lines used in this study are: adenocarcinoma MDA-MB-231 (TNBC, 
mesenchymal like/claudin low-KRAS mutation); medullary carcinoma MDA-MB-157 (TNBC, 
mesenchymal like/claudin low); adenocarcinoma MDA-MB-468 (TNBC, basal like—amplification of 
EGFR). Cell lines were kindly provided by the laboratory of Prof. G. Del Sal (Laboratorio Nazionale 
CIB (LNCIB) Area Science Park, Trieste, Italy). Cells were cultured as previously described [101]: 
MDA-MB-231 and MDA-MB-157 cells were grown in Dulbecco's Modified Eagle Medium (DMEM) 
plus 10% tetracycline-free fetal bovine serum (FBS), MDA-MB-468 cells in Roswell Park Memorial 
Institute (RPMI) 1640 medium plus 10% tetracycline-free FBS. Silencing experiments were carried 
out essentially as previously described [28]; briefly, cell lines were transfected with 100 nM siRNAs 
with LipofectamineTM RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA) and collected after 72 
hours. All siRNA sequences are reported in supplementary data. All the inhibitors used are listed in 
supplementary data. 
4.2. qRT-PCR, Cell proliferation (MTS) assay, Wound Healing Assay, Transwell Migration Assay, 
SDS-PAGE, and Western Blot Analyses 
These analyses were performed with conventional procedures essentially as previously 
described [28,29]. Briefly, total RNA was extracted using Trizol reagent (Invitrogen, Carlsbad, CA, 
USA), treated with DNase I (Invitrogen, Carlsbad, CA, USA), and subsequently purified with a 
conventional phenol-chloroform extraction method. qPCR was performed using iQTM SYBR Green 
Supermix (Bio-Rad Laboratories, Hercules, CA, USA), the data obtained were analysed with the 
Bio-Rad CFX Manager software and the relative gene expression was calculated by the ΔΔCt 
method. The primer sequences are reported in supplementary data. Cell proliferation was 
monitored using the MTS assay. 7000 cells were seeded into 96-well plate and left grown for 72 h. 
Cell viability was determined by CellTiter 96 Aqueous One Solution Assay (Promega, Madison, WI, 
USA) according to the manufacturer’s instructions. Briefly, after 0, 24, 48, or 72 h of incubation in 
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the growth medium with or without BI-D1870 10 μM, 120 µL of MTS solution (MTS reagent diluted 
1:6 in PBS containing 4.5 g/L glucose) was added into each well, the plate was incubated for 2h at 37 
°C in 5% CO2 atmosphere, and then absorbance at 480 nm was recorded with an INFINITE M200 
PRO microplate reader (Tecan Group Ltd., Männedorf, Switzerland). Wound healing assays were 
performed on 3 mL cell culture plates with cells at about 80% confluence. The cells were scraped 
with a 200 μL tip, and wound closure was followed for 8 hours. Measurements were made 
calculating the area in the middle part of the wounds selecting as much as possible straight and 
homogeneous zones. Reference points were used to select starting and ending lines for the area 
measurements. For transwell migration assays, 24-well polyethylene terephthalate (PET) inserts 
were used (8.0 μm pore size, Falcon (Corning), Corning, NY, USA) with matrigel-coated filters. 
40,000 cells were seeded and after 20 h migrated cells were fixed in PFA 4% and stained with 
Crystal Violet 0.5% (Sigma Aldrich, St. Louis, MO, USA). For sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) analyses, cells were washed in chilled 
phosphate-buffered saline (PBS) buffer and lysed using SDS sample buffer. SDS-PAGE analyses 
were made with T = 15% SDS Tris-Tricine polyacrylamide minigels. For western blot analyses, 
protein where transferred onto nitrocellulose membranes, stained with red ponceau, images 
acquired with a densitometric scanner, and then subjected to antibodies recognition. The antibodies 
used are listed in supplementary data. 
4.3. Immunofluorescence (IF) Analyses 
Cells cultured on glass coverslips were rinsed twice in PBS and fixed for 20 minutes at room 
temperature (RT) with 4% paraformaldehyde (PFA) in PBS pH 7.2. Cells were washed three times 
in PBS and then 0.1 M glycine was added for 5 minutes at RT. After three washes in PBS, cells were 
permeabilised with 0.3% Triton X for 5 minutes at RT. Cells were washed three times and unspecific 
sites were blocked with 0.5% (w/v) bovine serum albumin (BSA) in PBS for 30 minutes at RT. Each 
coverslip was incubated for 90 minutes in a wet chamber with the primary antibodies diluted in 
blocking solution. After three washes with PBS, samples were incubated with secondary antibody 
diluted in blocking solution for 60 minutes in a wet chamber. Coverslips were washed three times 
in PBS and incubated 5 minutes with 0.2 μg/mL Hoechst (Sigma Aldrich, St. Louis, MO, USA) in 
PBS. Images were acquired with an Eclipse Ti inverted research microscope (Nikon, Tokyo, Japan) 
equipped with a NIS-Elements software. The antibodies used for immunofluorescence analyses are 
listed in supplemental data. The nuclear/cytoplasmic mask was obtained using Hoechst staining to 
identify the nucleus and subtracting this region from the whole cellular area stained with the RSK2 
antibody to identify the cytoplasmic portion of the cell. 
4.4. Co-immunoprecipitation Assay  
Co-immunoprecipitations were carried out essentially as previously described [102]. A 
150-mm plate of cells at sub-confluence, was rinsed twice in cold PBS and collected with scraper. 
Cells were pelleted (4 °C, 450 g, 5 min) and washed again in PBS. Supernatant was discarded and 
cells resuspended in lysis buffer (25 mM Tris/HCl pH 8, 0.5% v/v NP40, 125 mM NaCl, 10% v/v 
glycerol) supplemented with 1/1000 (v/v) Phenylmetylsulfonyl fluoride (PMSF, saturated solution 
in isopropanol), 1 mM NaVO3, 5 mM NaF, 10 mM sodium butyrate and 1/100 (v/v) protease 
inhibitor cocktail (Sigma Aldrich, St. Louis, MO, USA) and incubated 15 minutes on ice. Samples 
were then sonicated at 30% of potency for 60 seconds (10 seconds ON, 30 seconds OFF) with a 
Branson Digital Sonifier 250 (Branson Ultrasonics, Danbury, CT, USA), centrifuged (4 °C, 8385 g, 10 
min), and supernatant collected and stored at −80°C. 30 μL of Protein G Sepharose (GE Healthcare, 
Chicago, IL, USA) were used for each co-immunoprecipitation. Beads were washed three times 
with Tris/HCl 50 mM pH 7 and incubated for one hour at 4 °C with 4 μg of α–HMGA1 antibody or 
IgGs (#ab37415, Abcam, Cambridge, UK) used as negative control, while the volume was adjusted 
with Tris/HCl 50 mM pH 7 to 500 μL. After centrifugation (4 °C, 1027 g, 1 min) supernatant was 
discarded and BSA 1 mg/mL in lysis buffer was added at 4 °C for 1 hour. Beads were then washed 
three times in lysis buffer (4 °C, 1027 g, 1 min). 500 μg of lysates, quantified by the bicinchoninic 
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acid (BCA) method, were adjusted to 1 mL with lysis buffer and incubated with beads for 3 hours. 
To verify that the interaction between proteins was not mediated by DNA a parallel experiment 
was performed using DNase I. For each co–IP, 500 μg of lysate adjusted to 500 μL with lysate buffer 
and DNase digestion buffer 10x (Invitrogen, Carlsbad, CA, USA) were digested with DNase I (1000 
U—Sigma Aldrich, St. Louis, MO, USA) for 20 minutes at 37 °C. An aliquot of 50 μL of lysate either 
digested or not (control without DNase) was kept and made 1% sarcosile and 25 mM 
ethylenediamine tetraacetic acid (EDTA). The aliquot was digested with 10 μg of RNase A (Sigma 
Aldrich, St. Louis, MO, USA) for 1 hour at 55 °C and later with 23 μg of Proteinase K (Sigma 
Aldrich, St. Louis, MO, USA) for 1 hour at 55 °C. 10 μL were conditioned with an equal volume of 
Blue/Orange DNA loading dye (Promega, Madison, WI, USA) and loaded to 1.5 % (w/v) agarose in 
tris-acetate-EDTA (TAE) buffer (1/25000 GelRed Biotium, Fremont, CA USA). Samples were 
subjected to electrophoretic separation for 40 minutes at 50 V. The visualization was done with a 
Gel Doc instrument (Bio-Rad Laboratories, Hercules, CA, USA). After the incubation with lysates, 
beads were centrifuged (4 °C, 1027 g, 1 min), supernatants were discarded and beads washed three 
times in lysis buffer. 20 μL of SDS sample buffer were added to each sample, heated for 5 minutes at 
96 °C and analysed by WB. 
4.5. Chromatin Immunoprecipitation 
Cells were fixed with 1% formaldehyde in serum–free medium, washed twice with PBS at 
room temperature (RT) and incubated with 125 mM Glycine/PBS (RT) for 5 min. After two washes 
with cold PBS, cells were gently scraped with cold PBS and pelleted (4 °C, 450 g, 10 min). Pellet was 
resuspended in 1 mL of cold Lysis Buffer (5 mM PIPES pH 6.8, 85 mM KCl, 0,5% NP40 (v/v)) 
supplemented with a protease inhibitor cocktail (PIC—Sigma Aldrich, St. Louis, MO, USA) and 
incubated for 10 min at 4 °C. Afterwards, nuclei were centrifuged (4 °C, 2100 g, 10 min) and 
resuspended in 1 ml cold RIPA 100 buffer (20 mM Tris-HCl pH 7.5, 100 mM NaCl, 1mM EDTA, 
0,5% NP40 (v/v), 0,05% Na-deoxycholate (v/v), 0,1% SDS (w/v)) supplemented with PIC. Samples 
were sonicated (Digital Sonifier 250, Branson Ultrasonics, Danbury, CT, USA) at 10% potency for 1 
min (10 sec ON, 30 sec OFF on ice, for six times). DNA fragments were checked by electrophoretic 
analyses. DNA samples were quantified with Qubit fluorometer (Invitrogen, Carlsbad, CA, 
USA—Quant-iTTM dsDNA BR Assay kit, #Q32850). For each ChIP, 80 µL of Protein A/G 1:1 
mixture (Protein G SepharoseTM 4 Fast Flow, #17-0618-01; Protein A SepharoseTM 4 Fast Flow 
#17-0974-01, GE Healthcare, Chicago, IL, USA) were washed (4° C, 1000 g, 2 min) twice with cold 
RIPA 100 and blocked by with 1 mL RIPA 100 (1 mg/ml Salmon Sperm DNA, 1 mg/mL BSA) for 1 h 
at 4° C. Equal amounts of cell lysate (2 Petri dishes) for each sample were precleared with blocked 
A/G beads for 1 h at 4° C. After incubation, samples were centrifuged (4° C, 1000 g, 2 min) and the 
precleared lysate was incubated o/n at 4° C with 3 µg of specific antibody or IgGs (#ab37415, 
Abcam, Cambridge, UK) as negative control. An aliquot from precleared lysate was conserved as 
input. Immunoprecipitation (IP): for each IP, 40 µL of A/G beads blocked o/n as described above, 
were washed twice with RIPA 100 and incubated with the lysate/antibody solution for 3 h at 4° C. 
Beads were washed twice with cold RIPA 100 supplemented with PIC, twice with cold RIPA 250 
(20 mM Tris-HCl pH7.5, 250 mM NaCl, 1mM EDTA, 0,5% NP40 (v/v), 0,05% Na-deoxycholate (v/v), 
0,1% SDS (w/v)) supplemented with PIC, and once with cold LiCl solution (10 mM Tris/HCl pH8, 1 
mM EDTA, 250 mM LiCl, 0,5% Na-deoxycholate (v/v), 0,5% NP40 (v/v)) for 10 min at 4° C. 
Afterwards, beads were washed with Tris/EDTA buffer (TE) (10 mM Tris/HCl pH 8, 1 mM EDTA 
pH 8) and resuspended in 100 mL TE. IP and input samples were complemented with 400 µL water 
and 20 µL NaCl 5 M. All samples were incubated at 65 °C o/n on a thermomixer. Samples were 
treated with RNase A and Proteinase K, phenol/chloroform extracted, and analysed by qPCR.  
4.6. Statistical Analysis 
Experimental data were evaluated by a two-tailed Student’s t-test, which provided means and 
standard deviations. WB histograms represent densitometry values of normalized bands versus 
densitometry of total lysates of ponceau-stained membrane. For both WB and qRT-PCR, the values 
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were normalized to the control samples. Immunofluorescence (IF) data were analysed by the 
Shapiro-Wilk test to check their probability distribution: with a p-value less than 0.05, they were 
considered not normally distributed, and non-parametric statistics were used, such as the 
Mann-Whitney test. Data are presented as boxplots, with median and whiskers from the 5th to 95th 
percentiles. 
5. Conclusions 
In conclusion, we provide a collection of evidence that the HMGA1 protein could promote the 
aggressiveness of BC cells by an epigenetic mechanism. More specifically, our data allow us to 
speculate that HMGA1 could be involved in the recruitment of histone modifiers onto chromatin. 
Given the difficulty of specifically targeting HMGA1 in breast cancer, we suggest that HMGA1 
expression could steer the choice of therapeutic approaches towards epigenetic–targeting options. 
Further work has to be done to in–deep evaluate the role of HMGA1 in influencing the epigenetic 
status of cancer cells. 
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